Ma Reyes García‐de‐la‐Fuente

ORCID: 0000-0002-7070-3110
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Nonmelanoma Skin Cancer Studies
  • Cancer and Skin Lesions
  • Polyomavirus and related diseases
  • Plant Pathogens and Fungal Diseases
  • Hedgehog Signaling Pathway Studies
  • Infectious Diseases and Mycology

Hospital Universitari Arnau de Vilanova
2017-2020

Biomedical Research Institute of Lleida
2017-2020

Basal cell carcinomas (BCC) are the most frequent tumours in humans and normally appear photoexposed areas of skin. It is widely accepted that BCCs originate at follicular stem cells consequently very rare nonhairy areas. Here, we report 4 cases vulvar BCC, 3 which were located a semimucous area, nonphotoexposed area. We have determined CK7 CK19 profile all cases; both markers simple epithelium with glandular differentiation. Interestingly, positively stained for CK19. Considering region...

10.1177/1203475417712498 article EN Journal of Cutaneous Medicine and Surgery 2017-06-01

Abstract: Basal cell carcinoma (BCC) seems to originate from ultraviolet light-induced mutations involving the bulge or outer sheath of hair follicle cells. However, etiopathogenic mechanisms involved in development these tumors nonphotoexposed and hairless areas remain unclear. The cytokeratin (CK) profile (including CK5/6, CK7, CK14, CK15, CK17, CK19) a series different BCC subtypes developing sun-exposed non–sun-exposed areas, including regions, was evaluated. authors have observed that...

10.1097/dad.0000000000001042 article EN American Journal of Dermatopathology 2017-11-14

Abstract Background/Objective Ingenol mebutate gel is approved for actinic keratosis field therapy, but little has been published as a treatment of basal cell carcinoma (BCC). Our objective to characterise the histopathological changes and infiltrating populations better understand its mechanism action. Methods Sixteen patients with various BCC subtypes were prospectively evaluated treated once daily two consecutive days ingenol 0.05% under occlusion. Patients randomised arms: first arm was...

10.1111/ajd.13229 article EN Australasian Journal of Dermatology 2020-01-16
Coming Soon ...